All articles by William Newton

William Newton is a Senior Reporter for Clinical Trials Arena and Pharmaceutical Technology, focusing on clinical trial design, healthcare business and regulation, and new technologies. Now based in New York City, he previously covered diabetes drug development at Close Concerns’ industry-facing publication in San Francisco. William holds a BA in Economics from Williams College.

William Newton


Neurona’s brain stem cell therapy shows early efficacy in epilepsy

Neurona’s stem cell therapy has promising early results in epilepsy, bolstering a growing push to develop cell therapies for neurological disorders.

Metformin could reduce long Covid rates, large study finds

Generic metformin could provide an affordable tool for preventing long Covid when taken at the time of Covid-19 infection.

VistaGen’s nasal spray could reduce menopausal hot flashes, new data suggests

In new Phase IIa data, VistaGen’s nasal spray reduced the average number of hot flashes in women with menopause.

ASCO 2023: Precigen reports positive early data for CAR-T therapy

Positive Phase I data could help propel development of Precigen’s CAR-T cell therapy PRGN-3005 in advanced ovarian cancer.

Akero’s NASH candidate and Ozempic reduce liver fat in Phase IIb cohort

New data shows the combination of Akero’s efruxifermin and Ozempic can reduce liver fat, boosting both drugs’ prospects in NASH.

Pharma world braces for major changes in new era of AI

Pharma industry leaders discussed value-adding use cases for AI in clinical development at the Outsourcing in Clinical Trials East Coast 2023 conference May 23–24.

China-based HanX earns FDA greenlight for US lymphoma trial

HanX Biopharmaceuticals has FDA approval for a US-based lymphoma trial, adding to the growing globalisation of the pharmaceutical industry.

Nexcella reports new data for CAR-T therapy in AL amyloidosis

Nexcella’s CAR-T cell therapy program gains momentum with a small set of early positive data in AL amyloidosis.

Galera earns key FDA designation for pancreatic cancer drug

Galera’s rucosopasem has earned FDA orphan drug designation for pancreatic cancer, bolstering an ongoing Phase IIb study.